Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / September 10, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Genomic Health, Inc. (NASDAQ: ...
- Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy - Oncotype DX® test recommended based on prospective landmark TAILORx and German Pla...
NEW YORK, NY / ACCESSWIRE / August 16, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Rudolp...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
NEW YORK , Aug. 9, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating: Genomic Health, Inc. ( GHDX ) ("Genomic"...
Merger activity decreased last week with three new deals announced and ten pending deals closing. Deal Statistics: New Deals: The acquisition of Genomic Health ([[GHDX]]) by Exact Sciences Corporation ([[EXAS]]) for $2.8 billion in a cash-plus-stock deal. Under the terms of the ...
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Genomic Health, Inc. (NASDAQ: GHDX) by Exact Sciences Corp. (NASDAQ: EXAS). On July 29, 2019, the two companies announced the signing of a definitive merger agreement pursuant to which Exact Sci...
NEW YORK, NY / ACCESSWIRE / August 1, 2019 / Halper Sadeh LLP, a global investor rights law firm, reminds investors that it is investigating the following companies: LegacyTexas Financial Group, Inc. (NASDAQ: LTXB) The investigation concerns whether LegacyTexas and i...
Cellectar Biosciences (NASDAQ: CLRB ) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up 8% premarket. More news on: Cellectar Biosciences, Inc., Heat Biologics, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th...
News, Short Squeeze, Breakout and More Instantly...
Genomic Health Inc. Company Name:
GHDX Stock Symbol:
NASDAQ Market:
Broadly, genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So what is genetics investing? When it comes to genetics investing, companies in this niche li...
Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wisconsin , Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its...
REDWOOD CITY, Calif. , Nov. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) announced that its stockholders voted to approve the company's proposed combination with Exact Sciences Corp (NASDAQ: EXAS) at a special meeting held earlier today. As previously announced...